Hui Chen1, Xiaoyan Zheng1, Ran Wang1, Na Gao1, Ziyang Sheng1, Dongying Fan1, Kaihao Feng1, Xianzheng Liao1, Jing An2. 1. Department of Microbiology and Parasitology, School of Basic Medical Sciences, Chinese Capital Medical University, Beijing 100069, PR China. 2. Department of Microbiology and Parasitology, School of Basic Medical Sciences, Chinese Capital Medical University, Beijing 100069, PR China; Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing 100069, PR China. Electronic address: anjing60@aliyun.com.
Abstract
PURPOSE: We aimed to use the dengue virus (DV) serotype 2 as a proof of principal for testing the efficacy of a DNA vaccine candidate via in vivo electroporation in mice and rabbits prior to the development of a tetravalent vaccine. METHODS: Different dosages of DNA pVAX1-D2ME encoding DV2 prME genes were vaccinated in mice via intramuscular injection or in vivo electroporation, immune responses and protection were determined. In DNA-vaccinated rabbits via electroporation, antibody titer and protein expression were tested. RESULTS: In mice, 50μg of pVAX1-D2ME via electroporation elicited effective anti-DV2 responses and conferred significant protection against DV2 challenge. Moreover, anti-DV2 IgG and neutralizing antibodies were successfully induced in rabbits immunized with pVAX1-D2ME via electroporation and the expression of the interest protein was observed at local sites. CONCLUSIONS: Enhanced immunogenicity and protective effect conferred by pVAX1-D2ME via electroporation show great promise for the development of a dengue tetravalent DNA vaccine.
PURPOSE: We aimed to use the dengue virus (DV) serotype 2 as a proof of principal for testing the efficacy of a DNA vaccine candidate via in vivo electroporation in mice and rabbits prior to the development of a tetravalent vaccine. METHODS: Different dosages of DNA pVAX1-D2ME encoding DV2 prME genes were vaccinated in mice via intramuscular injection or in vivo electroporation, immune responses and protection were determined. In DNA-vaccinated rabbits via electroporation, antibody titer and protein expression were tested. RESULTS: In mice, 50μg of pVAX1-D2ME via electroporation elicited effective anti-DV2 responses and conferred significant protection against DV2 challenge. Moreover, anti-DV2 IgG and neutralizing antibodies were successfully induced in rabbits immunized with pVAX1-D2ME via electroporation and the expression of the interest protein was observed at local sites. CONCLUSIONS: Enhanced immunogenicity and protective effect conferred by pVAX1-D2ME via electroporation show great promise for the development of a dengue tetravalent DNA vaccine.